Ambit
Driving breakthroughs in cancer and inflammatory disease treatment through pioneering kinase inhibitor research and innovative clinical collaborations.
197 employees · est. 2000
DeuterOncology NV
Developing deuterated BEST in CLASS MET kinase Inhibitor
5 employees · est. 2020 · Liege, Belgium
Ambit is the older company (2000 vs 2020); Ambit is the larger of the two.
Side-by-Side Comparison
| Metric | Ambit | DeuterOncology NV |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2020 |
| Headquarters | ||
| Headquarters | Not tracked yet | Liege, Belgium |
| Employees | ||
| Employees | 197 larger | 5 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series Unknown | Series A |
| Total Funding | ||
| Total Funding | $215.73M | $5.65M |
| Funding Rounds | ||
| Funding Rounds | 10 | 2 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Kinase Inhibitors, Cancer Treatment, Inflammatory Disease, Clinical Trials, FLT3 Inhibitor, Oncology, Astellas Pharma Inc., Small Molecule Drugs, AC220, AC480, AC430, JAK2 Inhibitor, Preclinical Pipeline, Drug Discovery | Deuterated, MET Kinase Inhibitor, Clinical Stage, Brain Penetrant, Cancer Therapy, Targeted Therapy, Drug Development, Small Molecules, Preclinical Stage, RAS Pathway Inhibitor, Clinical Development, Biotech Company, Timothy Perera, Liege Based |
| Website | ||
| Website | ambitbio.com | deuteroncology.com |
About Ambit
Ambit Biosciences is a biopharmaceutical company founded in 2000 with a focus on discovering and developing small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other conditions. The company's lead compound, AC220, is a highly selective FMS-like tyrosine kinase-3 (...
About DeuterOncology NV
DeuterOncology is a biotechnology startup based in Liege, Belgium, founded in 2020 with the aim of developing deuterated BEST in CLASS MET kinase Inhibitor. The company, led by Dr. Timothy Perera, is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET...
We will tell you when either one moves
BounceWatch watches Ambit and DeuterOncology NV for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Ambit and DeuterOncology NV — by email.
Frequently Asked Questions
Compare Ambit with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Ambit on 12 Sep 2024, and DeuterOncology NV on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
